<DOC>
	<DOC>NCT01579591</DOC>
	<brief_summary>This is a randomized, double-blind, placebo-controlled phase III study involving 160 patients designed to assess the efficacy of the high potency probiotic preparation VSL#3® versus placebo in increasing the pathological major response rate in patients undergoing concurrent CT and pelvic RT.</brief_summary>
	<brief_title>VSL#3 Versus Placebo in Increasing the Pathological Major Response Rate in Patients With Rectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Rectal Neoplasms</mesh_term>
	<criteria>Age &gt; 18 years Ability to sign informed consent and understand the nature of a placebo controlled trial. Ability to complete questionnaire(s) by themselves or with assistance. Life expectancy ≥ 6 months. Current diagnosis of cancer that supports the use of continuous definitive or adjuvant externalbeam RT to the pelvis to a minimum dose of 4500 cGy delivered with conventional multifield photon radiotherapy, 3D conformal photon radiotherapy or intensity modulated photon therapy. Will receive concurrent administration of chemotherapy (5FU, capecitabine, cisplatin, oxaliplatin, carboplatin, and/or mitomycin) during pelvic RT The following laboratory values obtained &gt; 28 days prior to registration: Hemoglobin &gt; 10.0 g/dL WBC &gt; 3,500 Absolute neutrophil count &gt; 1,500 Platelets &gt; 100,000 ECOG Performance Status (PS) of 0, 1 or 2 Willing to abstain from ingestion of yogurt products and/or any product containing probiotics during study drug treatment. Current or prior metastases beyond regional lymph nodes. Undergone abdominalperineal resection, Hartmann procedure, or other surgical procedure leaving the patient without a functioning rectum. Known allergy to a probiotic preparation. Any history of inflammatory bowel disease. &gt; grade 3 diarrhea, rectal bleeding, abdominal cramping, or incontinence of stool, ≤7 days prior to registration. Any medical condition that may interfere with ability to receive protocol treatment. Planned use of leucovorin (because of the risk of secretory diarrhea). Splitcourse RT is planned. Prior pelvic RT. Proton RT. Any of the following: Pregnant women Nursing women Men or women of childbearing potential who are unwilling to employ adequate contraception Use of probiotics ≤ 2 weeks prior to registration. Use of antibiotics ≤ 1 week prior to registration. Planned continuous antibiotic treatment during RT. History of gastrointestinal or genitourinary obstruction or porphyria.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
</DOC>